Cited by 81

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Critical off‐target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets

Dütting, S., Heidenreich, J., Cherpokova, D., Amin, E., Zhang, S.‐C., Ahmadian, M.R., Brakebusch, C., Nieswandt, B.·2015·Journal of Thrombosis and Haemostasis

Abstract

Background Platelet aggregation at sites of vascular injury is essential for normal hemostasis, but may also cause pathologic vessel occlusion. Rho GTPases are molecular switches that regulate essential cellular processes, and they have pivotal functions in the cardiovascular system. Rac1 is an important regulator of platelet cytoskeletal reorganization, and contributes to platelet activation. Rac1 inhibitors are thought to be beneficial in a wide range of therapeutic settings, and have therefore been tested in vivo for a variety of disorders. Two small-molecule inhibitors, NSC23766 and EHT1864, have been characterized in different cell types, demonstrating high specificity for Rac1 and Rac, respectively. Objectives To analyze the specificity of NSC23766 and EHT1864. Methods Platelet function was assessed in mouse wild-type and Rac1-deficient platelets by the use of flow cytometric analysis of cellular activation and aggregometry. Platelet spreading was analyzed with differential interference contrast microscopy, and activation of effector molecules was analyzed with biochemical approaches. Results NSC23766 and EHT1864 showed strong and distinct Rac1-independent effects at 100 μm in platelet function tests. Both inhibitors induced Rac1-specific inhibition of platelet spreading, but also markedly impaired agonist-induced activation of Rac1(-/-) platelets. Furthermore, glycoprotein Ib-mediated signaling was dramatically inhibited by NSC23766 in both wild-type and Rac1-deficient…

Overview

Integrity signals

Registry

Crossref · 10.1111/jth.12861

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 40

  1. Jackson, 2011, Arterial thrombosis – insidious, unpredictable and deadly, Nat Med, 17, 1423, 10.1038/nm.2515 · DOI
  2. Nieswandt, 2011, Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke, J Thromb Haemost, 9, 92, 10.1111/j.1538-7836.2011.04361.x · DOI
  3. Nieswandt, 2005, Platelets in atherothrombosis: lessons from mouse models, J Thromb Haemost, 3, 1725, 10.1111/j.1538-7836.2005.01488.x · DOI
  4. Etienne‐Manneville, 2002, Rho GTPases in cell biology, Nature, 420, 629, 10.1038/nature01148 · DOI · Paper page
  5. McCarty, 2005, Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow, J Biol Chem, 280, 39474, 10.1074/jbc.M504672200 · DOI
  6. Pleines, 2013, Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42, Blood, 122, 3178, 10.1182/blood-2013-03-487942 · DOI
  7. Pleines, 2010, Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets, Blood, 115, 3364, 10.1182/blood-2009-09-242271 · DOI
  8. Pleines, 2009, Rac1 is essential for phospholipase C‐gamma2 activation in platelets, Pflugers Arch, 457, 1173, 10.1007/s00424-008-0573-7 · DOI
  9. Pleines, 2012, Megakaryocyte‐specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis, Blood, 119, 1054, 10.1182/blood-2011-08-372193 · DOI
  10. Akbar, 2007, Genetic and pharmacologic evidence that Rac1 GTPase is involved in regulation of platelet secretion and aggregation, J Thromb Haemost, 5, 1747, 10.1111/j.1538-7836.2007.02646.x · DOI
  11. Brown, 2006, The Rac and Rho hall of fame: a decade of hypertrophic signaling hits, Circ Res, 98, 730, 10.1161/01.RES.0000216039.75913.9e · DOI
  12. Gao, 2004, Rational design and characterization of a Rac GTPase‐specific small molecule inhibitor, Proc Natl Acad Sci USA, 101, 7618, 10.1073/pnas.0307512101 · DOI · Paper page
  13. Pandey, 2009, Unraveling a novel Rac1‐mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin‐stimulated platelets, Blood, 114, 415, 10.1182/blood-2008-10-183582 · DOI
  14. Rahman, 2014, The small GTPase Rac1 is required for smooth muscle contraction, J Physiol, 592, 915, 10.1113/jphysiol.2013.262998 · DOI
  15. Levay, 2013, NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors, J Pharmacol Exp Ther, 347, 69, 10.1124/jpet.113.207266 · DOI
  16. Chrostek, 2006, Rac1 is crucial for hair follicle integrity but is not essential for maintenance of the epidermis, Mol Cell Biol, 26, 6957, 10.1128/MCB.00075-06 · DOI
  17. Tiedt, 2007, Pf4‐Cre transgenic mice allow the generation of lineage‐restricted gene knockouts for studying megakaryocyte and platelet function in vivo, Blood, 109, 1503, 10.1182/blood-2006-04-020362 · DOI
  18. Knight, 1999, Collagen–platelet interaction: Gly‐Pro‐Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen, Cardiovasc Res, 41, 450, 10.1016/S0008-6363(98)00306-X · DOI
  19. Nieswandt, 2000, Identification of critical antigen‐specific mechanisms in the development of immune thrombocytopenic purpura in mice, Blood, 96, 2520, 10.1182/blood.V96.7.2520 · DOI
  20. Gruner, 2004, Anti‐glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy, Circulation, 110, 2946, 10.1161/01.CIR.0000146341.63677.3C · DOI
  21. Jaiswal, 2012, Biochemical assays to characterize Rho GTPases, Methods Mol Biol, 827, 37, 10.1007/978-1-61779-442-1_3 · DOI
  22. Zhang, 2014, Liposome reconstitution and modulation of recombinant prenylated human Rac1 by GEFs, GDI1 and Pak1, PLoS One, 9, e102425, 10.1371/journal.pone.0102425 · DOI
  23. Thakur, 2014, The centrosomal adaptor TACC3 and the microtubule polymerase chTOG interact via defined C‐terminal subdomains in an Aurora‐A kinase‐independent manner, J Biol Chem, 289, 74, 10.1074/jbc.M113.532333 · DOI
  24. Marondedze, 2013, Comparative gel‐based phosphoproteomics in response to signaling molecules, Methods Mol Biol, 1016, 139, 10.1007/978-1-62703-441-8_10 · DOI
  25. Haga, 2012, Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist, Nature, 482, 547, 10.1038/nature10753 · DOI
  26. Montalvo‐Ortiz, 2012, Characterization of EHop‐016, novel small molecule inhibitor of Rac GTPase, J Biol Chem, 287, 13228, 10.1074/jbc.M111.334524 · DOI · Paper page
  27. Shattil, 2010, The final steps of integrin activation: the end game, Nat Rev Mol Cell Biol, 11, 288, 10.1038/nrm2871 · DOI · Paper page
  28. Aslan, 2011, S6K1 and mTOR regulate Rac1‐driven platelet activation and aggregation, Blood, 118, 3129, 10.1182/blood-2011-02-331579 · DOI
  29. Stefanini, 2012, Rap1–Rac1 circuits potentiate platelet activation, Arterioscler Thromb Vasc Biol, 32, 434, 10.1161/ATVBAHA.111.239194 · DOI
  30. Cohen, 1979, The contractile system of blood platelets and its function, Methods Achiev Exp Pathol, 9, 40
  31. Flevaris, 2009, Two distinct roles of mitogen‐activated protein kinases in platelets and a novel Rac1–MAPK‐dependent integrin outside‐in retractile signaling pathway, Blood, 113, 893, 10.1182/blood-2008-05-155978 · DOI
  32. Yuan, 1999, The von Willebrand factor–glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX‐transfected cells, J Biol Chem, 274, 36241, 10.1074/jbc.274.51.36241 · DOI
  33. McCarty, 2006, von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively, J Thromb Haemost, 4, 1367, 10.1111/j.1538-7836.2006.01966.x · DOI
  34. Delaney, 2012, The role of Rac1 in glycoprotein Ib–IX‐mediated signal transduction and integrin activation, Arterioscler Thromb Vasc Biol, 32, 2761, 10.1161/ATVBAHA.112.254920 · DOI
  35. Heasman, 2008, Mammalian Rho GTPases: new insights into their functions from in vivo studies, Nat Rev Mol Cell Biol, 9, 690, 10.1038/nrm2476 · DOI · Paper page
  36. Shibata, 2008, Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease, Nat Med, 14, 1370, 10.1038/nm.1879 · DOI
  37. Tan, 2012, Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain, J Neurosci, 32, 6795, 10.1523/JNEUROSCI.1017-12.2012 · DOI
  38. Binker, 2008, Inhibition of Rac1 decreases the severity of pancreatitis and pancreatitis‐associated lung injury in mice, Exp Physiol, 93, 1091, 10.1113/expphysiol.2008.043141 · DOI
  39. Colomba, 2011, Inhibition of Rac controls NPM‐ALK‐dependent lymphoma development and dissemination, Blood Cancer J, 1, e21, 10.1038/bcj.2011.19 · DOI
  40. Kumar, 2006, p21‐activated kinases in cancer, Nat Rev Cancer, 6, 459, 10.1038/nrc1892 · DOI

Cited by

See all 81

Metadata

Authors
Dütting, S., Heidenreich, J., Cherpokova, D., Amin, E., Zhang, S. ‐., Ahmadian, M. R., Brakebusch, C., & Nieswandt, B.
Venue
Journal of Thrombosis and Haemostasis
Publisher
Elsevier BV
Published
2015-05
Volume
13
Issue
5
Pages
827-838
ISSN
1538-7836
Cited by
81
References
2
Language
en
Funders
  • Deutsche Forschungsgemeinschaft (Ni556/9-1)
  • Nieswandt and Sonderforschungsbereich [SFB] (688)
  • International Research Training Group [IRTG] (1902)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review